Michael Rice
CEO at BioLife Solutions Inc.
Sits on 1 board. Last updated September 27, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: BioLife Solutions Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
BioLife Solutions Inc. July 21, 202396.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 30, 2023 | BioLife Solutions Inc. | Open-market sale | −72,603 | $9.13 | $662,865 |
| Oct 22, 2023 | BioLife Solutions Inc. | Grant or award | +771 | — | — |
| Oct 8, 2023 | BioLife Solutions Inc. | Grant or award | +282 | — | — |
| Sep 28, 2023 | BioLife Solutions Inc. | Open-market sale | −831 | $14.16 | $11,767 |
| Sep 24, 2023 | BioLife Solutions Inc. | Grant or award | +290 | — | — |
| Sep 10, 2023 | BioLife Solutions Inc. | Grant or award | +1,022 | — | — |
| Aug 27, 2023 | BioLife Solutions Inc. | Grant or award | +1,248 | — | — |
| Aug 25, 2023 | BioLife Solutions Inc. | Open-market sale | −1,729 | $10.99 | $19,002 |
| Aug 14, 2023 | BioLife Solutions Inc. | Open-market sale | −277 | $12.38 | $3,429 |
| Jun 27, 2023 | BioLife Solutions Inc. | Open-market sale | −877 | $22.91 | $20,092 |
| May 31, 2023 | BioLife Solutions Inc. | Open-market sale | −1,679 | $23.21 | $38,970 |
| May 17, 2023 | BioLife Solutions Inc. | Open-market sale | −33,333 | $21.04 | $701,326 |
| May 15, 2023 | BioLife Solutions Inc. | Open-market sale | −190 | $18.71 | $3,555 |
| Apr 6, 2023 | BioLife Solutions Inc. | Open-market sale | −3,214 | $20.03 | $64,376 |
| Mar 29, 2023 | BioLife Solutions Inc. | Open-market sale | −936 | $20.62 | $19,300 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.